Timing is everything: new trial seeks best day for immunotherapy in nose cancer
NCT ID NCT07388836
First seen Feb 05, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This study tests whether giving the immunotherapy drug toripalimab on day 1, 5, or 9 of chemotherapy cycles improves tumor shrinkage in people with advanced nasopharyngeal cancer. About 198 adults will receive 3 cycles of chemo plus toripalimab, followed by standard chemoradiation. The goal is to find the optimal timing to boost treatment response without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.